GlaxoSmithKline plc – Annual report – 31 December 2024
Industry: pharmaceuticals
43. Reconciliation of net cash flow to movement in net debt
(1) Repayment of long-term loans for 2024 of £1,615 million (2023: £2,260 million; 2022: £6,668 million) includes the current portion of long-term borrowings of £1,615 million (2023: £2,116 million; 2022: £5,074 million) which was classified as short-term borrowing on the balance sheet and previously presented as repayment of short-term loans
(2) Other short-term loans include bank loans presented within short-term borrowings on the balance sheet, with an initial maturity of greater than three months.
* Excluding cash and cash equivalents, overdrafts and liquid investments.
* Excluding cash and cash equivalents, overdrafts and liquid investments.
For further information on significant changes in net debt see Note 30, ‘Net debt’.
Accounts examples 